Kopp Investment Advisors buys $11,844,754 stake in NeoGenomics (NEO)

NeoGenomics (NEO) : Kopp Investment Advisors scooped up 48,354 additional shares in NeoGenomics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,476,902 shares of NeoGenomics which is valued at $11,844,754.NeoGenomics makes up approximately 5.37% of Kopp Investment Advisors’s portfolio.

Other Hedge Funds, Including , Highbridge Capital Management sold out all of its stake in NEO during the most recent quarter. The investment firm sold 24,743 shares of NEO which is valued $198,439.Renaissance Technologies boosted its stake in NEO in the latest quarter, The investment management firm added 172,500 additional shares and now holds a total of 507,200 shares of NeoGenomics which is valued at $4,067,744. NeoGenomics makes up approx 0.01% of Renaissance Technologies’s portfolio.Tiaa Cref Investment Management reduced its stake in NEO by selling 4,023 shares or 2.4% in the most recent quarter. The Hedge Fund company now holds 163,263 shares of NEO which is valued at $1,309,369. Blackrock Group Ltd added NEO to its portfolio by purchasing 11,522 company shares during the most recent quarter which is valued at $92,406.Royce Associates Lp boosted its stake in NEO in the latest quarter, The investment management firm added 181,000 additional shares and now holds a total of 654,000 shares of NeoGenomics which is valued at $5,303,940. NeoGenomics makes up approx 0.03% of Royce Associates Lp’s portfolio.

NeoGenomics closed down -0.09 points or -1.12% at $7.95 with 2,06,931 shares getting traded on Thursday. Post opening the session at $8, the shares hit an intraday low of $7.81 and an intraday high of $8.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, NeoGenomics reported $0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.03. The company had revenue of $63.13 million for the quarter, compared to analysts expectations of $60.94 million. The company’s revenue was up 159.0% compared to the same quarter last year.

Many Wall Street Analysts have commented on NeoGenomics. Company shares were Reiterated by The Benchmark Company on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 12 from a previous price target of $10 .

NeoGenomics Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company offers testing services which includes Cytogenetics testing which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing which is a process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to in biological tissues. and molecular testing which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA) as well as the structure and function of genes at a molecular level.

Leave a Reply

NeoGenomics - Is it time to Sell?

Top Brokerage Firms are advising their investors on NeoGenomics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.